Jiutian Chemical’s FY20 core net profit of RMB155m was below our expectations (78% of our full-year forecast) mainly due to lower-than-expected gross profit margin in 4Q20.
We remain positive as near-term ASP outlook remains strong. As of 18 Feb, dimethylformamide (DMF) prices in Southern China stood at RMB10,200 (+25% year-to-date, +82% y-o-y).
Maintain ADD with a lower target price of S$0.135 (pegged to 5.7x FY22F P/E).
Boosted by higher ASPs, Jiutian Chemical (SGX:C8R) reported a 4Q20 net profit of RMB86m (+66% q-o-q). FY20 core net profit came in at RMB155m, a reversal over FY19's net loss position.
Nevertheless, we deem the set of results as below expectations vs our full-year forecast of RMB200m. The key disappointment was lower-than-expected gross profit margin in 4Q20, attributable to higher raw material costs during the quarter.
Near-term Outlook Remains Positive
We remain positive on near-term ASP outlook, as we expect downstream demand to stay robust riding on a recovery of China’s economy, as well as rising demand for methylamine (MA) products from fast-growing sectors including electric vehicle (EV) batteries, semiconductor, pharmaceuticals and animal feeds.
As of 18 Feb 2021, the dimethylformamide (DMF) asking price (inclusive of 13% value added tax) in Southern China stood at RMB10,200/ton (+25% year-to-date, +82% y-o-y) according to Oilchem.net, an online platform for energy and chemical information in China.
We forecast Jiutian Chemical to report a net profit of RMB222m (+28% y-o-y) in FY21F.
Aggressive Capacity Expansion Plans
In view of the favourable operating environment, Jiutian Chemical is in the process of finalising an expansion plan comprising a new 100kt MA plant adjacent to its net cash of RMB110m (as of end-FY20), supplemented by its cash generation in FY21-22F.
We have yet to factor in the capacity expansion plan into our forecasts.
Maintain ADD With a Lower Target Price of S$0.135
Maintain ADD on Jiutian Chemical as it rides on a cyclical assumptions. Our target price is lowered to S$0.135, still pegged to 5.7x FY22F P/E (20% discount to SGX-listed peer China Sunsine (SGX:QES)).
Potential catalysts include continued uptrend in DMF company Anyang JiuJiu, with management expecting a resumption of operations in 1H21F.
Downside risks include a sharp decline of DMF ASPs and higher raw material cost pressure.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....